HIT on dialysis - When is it safe to re-challenge? See Hartmann et al., pp. c143-c148

Nephron - Clinical Practice

Volumn 104, Issue 4, 2006, Pages

  Davenport, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HEPARINOID; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ANTICOAGULATION; BLEEDING; DIALYSIS; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; LUNG EMBOLISM; NOTE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PSEUDOPULMONARY EMBOLUS SYNDROME; THROMBOCYTE AGGLUTINATION; THROMBOCYTE COUNT;

AGED; ANTICOAGULANTS; AUTOANTIBODIES; DRUG TOXICITY; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 33845314715     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094960     Document Type: Note

References (10)

1. Davenport A: Heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 2004;8:295-303.
2. Boon DM, van Vliet HH, Zietse R, Kappers-Klunne MC: The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemostat 1996;76:480.
3. O'Shea SI, Sands JJ, Nudo SA, Ortel TL: Frequency of antiheparin platelet factor 4 antibodies in haemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Haematol 2002;69:72-73.
4. Palomo I, Pereira J, Alarcon M, Diaz G, Hidalgo P, Pizarro I, Jara E, Rojas P, Quiroga G, Moore-Carrasco R: Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 2005;19:189-195.
5. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T: Heparin induced thrombocytopenia in haemodialysis patients. Am J Kidney Dis 1996;28:82-85.
6. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):311S-337S.
7. Davenport A: Management of heparin-induced thrombocytopenia during continuous renal replacement therapy. Am J Kidney Dis 1998;32:E3.
8. Davenport A: Sudden collapse during haemodialysis due to immune-mediated heparin-induced thrombocytopaenia. Nephrol Dial Transplant 2006;21:1721-1724.
9. Davenport A: The management of heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 2001;5:81-85.
10. Hartman V, Malbrain M, Daelemans R, Meersman P, Zachée P: Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006;104:c143-c148.